Recent Press Releases

FDA Approves Expanded Label for AZILECT® for Treatment Across All Stages of Parkinson's Disease

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for AZILECT® (rasagiline...

Merck to Acquire Idenix

Merck to Acquire Idenix Acquisition Expands Portfolio of Promising Investigational Therapies for Hepatitis C WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass., Jun 09, 2014 (BUSINESS WIRE) -- Merck MRK...

FDA Approves Biogen Idec's Eloctate™, First Hemophilia A Therapy to Extend the Interval Between Prophylactic Infusions, for Both Adults and Children

FDA APPROVES BIOGEN IDEC'S ELOCTATE™, FIRST HEMOPHILIA A THERAPY TO EXTEND THE INTERVAL BETWEEN PROPHYLACTIC INFUSIONS, FOR BOTH ADULTS AND CHILDREN – Only Hemophilia A Therapy to...

Amgen To Present At The Goldman Sachs Global Healthcare Conference

THOUSAND OAKS, Calif., June 6, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sach

Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism

Pradaxa® is a simple treatment option that is as effective as warfarin with significantly lower bleeding rates, a major advance for DVT and PE patients 1–4 EU approval follows recent...

Ranbaxy, Toansa assessment concluded: no risk to public health

Ranbaxy, Toansa assessment concluded: no risk to public health European regulatory authorities have finalised their assessment of reported non-compliance with Good Manufacturing Practice (GMP) at...

Luqa Pharmaceuticals announces first launches in Hong Kong S.A.R.

Luqa Pharmaceuticals announces first launches in Hong Kong S.A.R. Hong Kong SAR – June 1st Company, announces the commencement of commercial operations in Hong Kong S.A.R. through the launch of...

Ampio Pharmaceuticals, Inc. (AMPE) Announces Appointment Of Gregory A. Gould As Chief Financial Officer

Ampio Pharmaceuticals, Inc. (AMPE) Announces Appointment Of Gregory A. Gould As Chief Financial Officer GREENWOOD VILLAGE, Colo., June 5, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT:...

Ironwood Pharmaceuticals Appoints Douglas Williams, Ph.D., to Board of Directors

Ironwood Pharmaceuticals Appoints Douglas Williams, Ph.D., to Board of Directors CAMBRIDGE, Mass., Jun 04, 2014 (BUSINESS WIRE) -- Ironwood Pharmaceuticals, Inc. IRWD +1.80% announced today the...

Québec Becomes First Province to Add Victoza® to the Drug Benefit Formulary* for the Treatment of Type 2 Diabetes

Québec Becomes First Province to Add Victoza® to the Drug Benefit Formulary* for the Treatment of Type 2 Diabetes MISSISSAUGA, ON, June 4, 2014 /CNW/ - Novo Nordisk today announces that...

Abbott to Present at William Blair 34th Annual Growth Stock Conference

ABBOTT PARK, Ill., June 4, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the William Blair 34th Annual Growth Stock

INVEGA® receives European Commission approval to extend its adult indication for treatment of schizophrenia to include adolescents aged 15 years and older

INVEGA® receives European Commission approval to extend its adult indication for treatment of schizophrenia to include adolescents aged 15 years and older Three pivotal Phase 3 studies...

Contract for CEO Dr. Marijn Dekkers extended to the end of 2016

Contract for CEO Dr. Marijn Dekkers extended to the end of 2016 Werner Baumann appointed as Chief Strategy and Portfolio Officer / Johannes Dietsch to be Chief Financial Officer Leverkusen, June 3,...

Surveyed Hematologists in China Expect the Market Entry of Generic Imatinib to Significantly Decrease Glivec's Patient Share in Chronic Myeloid Leukemia

Surveyed Hematologists in China Expect the Market Entry of Generic Imatinib to Significantly Decrease Glivec's Patient Share in Chronic Myeloid Leukemia High Cost and High Expectations for...

Oncothyreon Announces Presentation of ONT-10 Data at ASCO Annual Meeting

SEATTLE, June 2, 2014 /PRNewswire/ - Oncothyreon Inc.

Amgen Presents New Data On Talimogene Laherparepvec As Single Agent And Combination Therapy In Metastatic Melanoma At ASCO

Phase 1 Study Evaluating Talimogene Laherparepvec Plus Ipilimumab Showed Tolerability at Doses Administered

THOUSAND OAKS, Calif.,

Lilly's CYRAMZA™ (ramucirumab) Significantly Improves Overall Survival In Phase III Non-Small Cell Lung Cancer Study

-- REVEL Data Published in The Lancet, Presented at Annual ASCO Meeting --

CHICAGO, June 2, 2014 /PR

Lilly Announces Increased Access to Clinical Trials Data for Qualified Researchers

INDIANAPOLIS, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will begin sh

Appoints Sigurdur Olafsson as President and CEO of Newly Established Global Generic Medicines Group

Appoints Sigurdur Olafsson as President and CEO of Newly Established Global Generic Medicines Group New, fully integrated Global Generic Medicines Group will be responsible for all global commercial...